{"id":"NCT01908816","sponsor":"Novartis Pharmaceuticals","briefTitle":"An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.","officialTitle":"An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-26","primaryCompletion":"2016-01-08","completion":"2016-01-08","firstPosted":"2013-07-26","resultsPosted":"2019-08-12","lastUpdate":"2019-08-12"},"enrollment":270,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Choroidal Neovascularization","Macular Edema","Glaucoma, Neovascular","Diabetic Retinopathy"],"interventions":[{"type":"DRUG","name":"ranibizumab","otherNames":[]}],"arms":[{"label":"ranibizumab","type":"EXPERIMENTAL"}],"summary":"The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.","primaryOutcome":{"measure":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability","timeFrame":"24 months","effectByArm":[{"arm":"CNV (Choroidal Neovascularization)","deltaMin":2,"sd":null},{"arm":"ME (Macular Edema)","deltaMin":21,"sd":null},{"arm":"RI/NVG (Rubeosis Iridis and Neovacular Glaucoma)","deltaMin":1,"sd":null},{"arm":"PDR/V","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":39,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":93},"commonTop":["Inappropriate schedule of drug administration (Study eye)","Drug ineffective (Study eye)","Eye pain (Study eye)","Headache","Incorrect product storage (Study eye)"]}}